当前位置: 首页 >> 检索结果
1. Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF: A Randomized Controlled Trial.
作者: Nicolas Derval.;Romain Tixier.;Josselin Duchateau.;Xavier Bouteiller.;Timothé Loock.;Arnaud Denis.;Rémi Chauvel.;Benjamin Bouyer.;Marine Arnaud.;Masaaki Yokoyama.;Christopher Kowalewski.;Cinzia Monaco.;Ciro Ascione.;Frédéric Sacher.;Mélèze Hocini.;Pierre Jaïs.;Michel Haïssaguerre.;Thomas Pambrun.
来源: Circ Arrhythm Electrophysiol. 2025年18卷5期e013427页
Beyond pulmonary vein (PV) isolation, the optimal ablation strategy for persistent atrial fibrillation (AF) remains poorly defined. The purpose of this study was to compare 2 ablation strategies in the treatment of patients with persistent AF: a comprehensive ablation strategy based on anatomic considerations versus PV isolation alone.
2. Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
作者: Jesper Kjaergaard.;Christian Holdflod Møller.;Sebastian Wiberg.;Astrid Duus Mikkelsen.;Hasse Møller-Sørensen.;Hanne Berg Ravn.;Jesper Ravn.;Peter Skov Olsen.;Dan E Høfsten.;Søren Boesgaard.;Lars Køber.;Jens Christian Nilsson.;Christian Hassager.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014961页
GLP-1 (glucagon-like peptide-1) agonists have been proven beneficial in reducing the risk of and injury associated with several cardiovascular diseases. The efficacy in cardiopulmonary bypass-assisted cardiac surgery is unknown. This trial aimed to investigate the efficacy of an infusion of the GLP-1 agonist exenatide during and after open-heart surgery in reducing the risk of death and major organ failure.
3. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
作者: Andre Zimerman.;Ana Laura F Kunzler.;Brittany N Weber.;Xinhui Ran.;Sabina A Murphy.;Huei Wang.;Narimon Honarpour.;Anthony C Keech.;Peter S Sever.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2025年151卷20期1467-1476页
Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events.
4. Impact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial.
作者: Gaoqiang Xie.;Anushka Patel.;Xin Du.;Yihong Sun.;Xian Li.;Tao Wu.;Zhixin Hao.;Runlin Gao.;Yangfeng Wu.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011441页
Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge.
5. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
作者: Leos Pleva.;Pavel Kukla.;Tomas Kovarnik.;Jana Zapletalova.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014677页
Current therapy for in-stent restenosis (ISR) is based on drug-eluting stents (DES) or drug-eluting balloon catheters. This prospective randomized study compared the efficacy of a novel sirolimus-eluting balloon (SEB) catheter to that of a paclitaxel-eluting balloon (PEB) catheter for the treatment of bare-metal stent (BMS-ISR) or DES-ISR.
6. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
作者: Signe Glargaard.;Jakob Hartvig Thomsen.;Christian Tuxen.;Matias Greve Lindholm.;Christian Axel Bang.;Morten Schou.;Kasper Iversen.;Rasmus Vedby Rasmussen.;Brian Bridal Løgstrup.;Søren Vraa.;Nis Stride.;Ekim Seven.;Anders Barasa.;Marlene Tofterup.;Dan Eik Høfsten.;Kasper Rossing.;Lars Køber.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷16期1150-1161页
TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.
7. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Brian R Lindman.;Philippe Pibarot.;Allan Schwartz.;J Bradley Oldemeyer.;Yan Ru Su.;Kashish Goel.;David J Cohen.;William F Fearon.;Vasilis Babaliaros.;David Daniels.;Adnan Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Michael J Mack.;Thom Dahle.;William W O'Neill.;Charles J Davidson.;Raj Makkar.;Tej Sheth.;Jeremiah Depta.;James T DeVries.;Jeffrey Southard.;Andrei Pop.;Paul Sorajja.;Rebecca T Hahn.;Yanglu Zhao.;Martin B Leon.;Philippe Généreux.; .
来源: Circulation. 2025年151卷22期1550-1564页
The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.
8. Short-Term DAPT After Complex PCI With Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial.
作者: Jung-Kyu Han.;Keehwan Lee.;Sang-Hyeon Park.;Seokhun Yang.;Doyeon Hwang.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Yong Hoon Kim.;Namho Lee.;Seung Jin Lee.;Sanghoon Shin.;Hyo-Soo Kim.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014623页
The optimal duration of dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI) remains unclear. We aim to investigate the efficacy and safety of 3 to 6 months of DAPT over 12 months after complex PCI.
9. Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: A Randomized Clinical Trial.
作者: Varsha Keelara Tanguturi.;Roukoz Abou-Karam.;Fangzhou Cheng.;Rong Duan.;Ignacio Inglessis-Azuaje.;Nathaniel B Langer.;Evin N Yucel.;Jonathan J Passeri.;Judy W Hung.;Sammy Elmariah.
来源: Circulation. 2025年151卷21期1498-1507页
Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPNs) on rates of AVR at 1 year.
10. Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial.
作者: Sunil V Rao.;Maria Mori Brooks.;Helen E A D'Agostino.;P Gabriel Steg.;Tabassome Simon.;Herbert D Aronow.;Andrew M Goldsweig.;Shahbaz Malik.;Caroline Alsweiler.;Kalon K L Ho.;Payam Dehghani.;Adriano Caixeta.;Ata R Quraishi.;Simon Robinson.;Jay H Traverse.;Omar Siddiqi.;Dean A Fergusson.;Brian J Potter.;Joshua Schulman-Marcus.;Friederike K Keating.;Jeffrey L Carson.; .
来源: Circ Cardiovasc Interv. 2025年18卷5期e015249页
The MINT trial (Myocardial Ischemia and Transfusion; N=3504) randomized patients with acute myocardial infarction (MI) and hemoglobin ≤10 g/dL to liberal (maintain hemoglobin ≥10 g/dL) or restrictive (maintain hemoglobin ≥8 g/dL) red blood cell transfusion. The results suggested a benefit on 30-day death or MI with a liberal transfusion strategy. The effect of transfusion in patients with acute MI undergoing revascularization is unclear.
11. Effect of Disclosing a Polygenic Risk Score for Coronary Heart Disease on Adverse Cardiovascular Events.
作者: Mohammadreza Naderian.;Marwan E Hamed.;Ali A Vaseem.;Kristjan Norland.;Ozan Dikilitas.;Azin Teymourzadeh.;Kent R Bailey.;Iftikhar J Kullo.
来源: Circ Genom Precis Med. 2025年18卷2期e004968页
In the Myocardial Infarction Genes clinical trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01936675), participants at intermediate risk of coronary heart disease (CHD) were randomized to receive a Framingham risk score (Framingham risk score group, n=103) or an integrated risk score (integrated risk score group [IRSg], n=104) that additionally included a polygenic risk score. After 6 months, IRSg participants had higher statin initiation and lower low-density lipoprotein cholesterol. We conducted a post hoc 10-year follow-up analysis to investigate whether disclosure of a polygenic risk score for CHD was associated with a reduction in major adverse cardiovascular events (MACE).
12. Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.
作者: Andrew M Goldsweig.;William J Kostis.;Brandon M Herbert.;Claire Bouleti.;Brian J Potter.;Jordan B Strom.;Jocelyne Benatar.;Thao Huynh.;Srikanth Vallurupalli.;Estêvão Lanna Figueiredo.;J Dawn Abbott.;Howard A Cooper.;Andrew P DeFilippis.;Dean A Fergusson.;Shaun G Goodman.;Paul C Hébert.;Renato D Lopes.;Sunil V Rao.;Tabassome Simon.;Jeffrey L Carson.;Maria Mori Brooks.;John H Alexander.; .
来源: Circ Heart Fail. 2025年18卷4期e012495页
Blood transfusion may precipitate adverse outcomes, including heart failure (HF), among patients with acute myocardial infarction (MI). This study characterizes the effects of a restrictive or liberal transfusion strategy on outcomes in patients with MI and anemia with and without baseline HF.
13. Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial.
作者: Yunpeng Zhu.;Wei Zhang.;Kaijie Qin.;Yun Liu.;Haoyi Yao.;Zhe Wang.;Xiaofeng Ye.;Mi Zhou.;Haiqing Li.;Jiapei Qiu.;Hong Xu.;Yanjun Sun.;Mario Gaudino.;Qiang Zhao.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014542页
The optimal antispastic treatment after coronary artery bypass grafting using radial artery (RA) grafts is controversial. This clinical trial aimed to generate pilot comparative data on the effects of nicorandil, isosorbide mononitrate, or diltiazem on RA grafts.
14. Enhancing Stroke Awareness and Activation Among High-Risk Populations: A Randomized Direct Mail Intervention in Diverse Healthcare Settings.
作者: Christine C Groves.;Teresa M Damush.;Laura J Myers.;Fitsum Baye.;Joanne K Daggy.;Anthony J Perkins.;Holly Martin.;Layne Mounsey.;Daniel O Clark.;Linda S Williams.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011425页
Many patients are unaware of their stroke risk. The purpose of this research was to compare the effect of behaviorally tailored mailed messages on patient activation to reduce stroke risk.
15. Operator Radiation Exposure Comparing the Left Radial Artery Approach and a Uniform Hyper-Adducted Right Radial Artery Approach: The HARRA Study.
作者: Richard Casazza.;Bilal Malik.;Arsalan Hashmi.;Joshua Fogel.;Enrico Montagna.;Robert Frankel.;Elliot Borgen.;Sergey Ayzenberg.;Michael Friedman.;Norbert Moskovits.;Shivani Verma.;Jamie Meng.;Nailun Chang.;Yili Huang.;Carlos Rodriguez.;Habib Hymie Chera.;Shiv Raj.;Saurav Chaterjee.;Daren Gibson.;Andres Palacios.;Chirag Agarwal.;Maria Victoria Nene.;Jacob Shani.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014602页
Radiation exposure is one of the most adverse occupational hazards faced by interventional cardiologists. Various arterial access sites have shown to yield different operator radiation exposure during diagnostic cardiac catheterization.
16. Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia.
作者: Michael S Conte.;Alik Farber.;Andrew Barleben.;Emiliano Chisci.;Gheorghe Doros.;Vikram S Kashyap.;Ahmed Kayssi.;Philippe Kolh.;Carla C Moreira.;Timothy Nypaver.;Kenneth Rosenfield.;Vincent L Rowe.;Andres Schanzer.;Niten Singh.;Jeffrey J Siracuse.;Michael B Strong.;Matthew T Menard.
来源: Circ Cardiovasc Interv. 2025年18卷3期e014716页
The optimal strategy for lower extremity revascularization (surgical bypass versus endovascular intervention) in patients with chronic limb-threatening ischemia (CLTI) is unclear. We examined the effectiveness of open surgical bypass using single-segment great saphenous vein conduit (SSGSV), alternative conduits (AC), or endovascular interventions (ENDO) among patients with CLTI deemed acceptable for either open surgical bypass or ENDO treatment.
17. Intravascular Imaging-Guided Versus Angiography-Guided Complex PCI in Patients With High Bleeding Risk: A Secondary Analysis of the RENOVATE-COMPLEX PCI Trial.
作者: Jinhwan Jo.;Sang Yoon Lee.;Woochan Kwon.;Seung-Jae Lee.;Jong-Young Lee.;Seung Hun Lee.;Doosup Shin.;Sang Min Kim.;Kyeong Ho Yun.;Jae Young Cho.;Chan Joon Kim.;Hyo-Suk Ahn.;Chang-Wook Nam.;Hyuck-Jun Yoon.;Yong Hwan Park.;Wang Soo Lee.;Ki Hong Choi.;Taek Kyu Park.;Jeong Hoon Yang.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.;Sang Yeub Lee.;Joo Myung Lee.; .
来源: Circ Cardiovasc Interv. 2025年18卷3期e014952页
Although patients with high bleeding risk (HBR) often have complex coronary artery lesions, it is not known whether intravascular imaging-guided percutaneous coronary intervention (PCI) improves their prognosis. We sought to investigate the benefit of intravascular imaging-guided PCI for complex coronary artery lesions in patients with HBR.
18. Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.
作者: Sanjiv J Shah.;Diana Bonderman.;Barry A Borlaug.;John G F Cleland.;Gabriela Lack.;Wentao Lu.;Adriaan A Voors.;Faiez Zannad.;Mark T Gladwin.
来源: Circ Heart Fail. 2025年18卷3期e011381页
Despite favorable hemodynamic and neurohormonal effects, endothelin receptor antagonists have not improved outcomes in patients with heart failure (HF), possibly because they cause fluid retention.
19. Patent Foramen Ovale Closure in Patients With and Without Nickel Hypersensitivity: A Randomized Trial.
作者: Anastasios Apostolos.;Stamatios Gregoriou.;Maria Drakopoulou.;Georgios Trantalis.;Aikaterini Tsiogka.;Nikolaos Ktenopoulos.;Konstantina Aggeli.;Alexander Stratigos.;Konstantinos Tsioufis.;Konstantinos Toutouzas.
来源: Circ Cardiovasc Interv. 2025年18卷4期e015228页
Nickel-containing devices, such as the Amplatzer PFO Occluder and Gore Cardioform Septal Occluder, are used for transcatheter patent foramen ovale closure. However, the impact of nickel hypersensitivity on postprocedural outcomes remains poorly understood. This study aimed to evaluate the risk of adverse events in patients with nickel hypersensitivity undergoing patent foramen ovale closure.
20. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy.
作者: Natasha L Altman.;Edward A Gill.;Rami Kahwash.;Leslie K Meyer.;Jessica A Wagner.;Anis Karimpour-Fard.;Amber A Berning.;Wayne A Minobe.;Ian A Carroll.;Eric R Jonas.;Dobromir Slavov.;Sitaramesh Emani.;William T Abraham.;Alexa R Gollah.;Samuel L Ellis.;Matthew R G Taylor.;Sharon L Graw.;Luisa Mestroni.;Timothy A McKinsey.;Peter M Buttrick.;David P Kao.;Michael R Bristow.
来源: Circ Heart Fail. 2025年18卷4期e012484页
Heart rate (HR) affects heart failure outcomes, via uncertain mechanisms that may include left ventricular remodeling. However, in human ventricular myocardium, HR change has not been associated with a particular remodeling molecular phenotype.
|